Pozzilli C, Prosperini L, Sbardella E, Paolillo A
Department of Neurological Sciences, La Sapienza University, Viale dell'Università 30, I-00185 Rome, Italy.
Neurol Sci. 2006 Sep;27 Suppl 5:S369-72. doi: 10.1007/s10072-006-0697-5.
Multiple sclerosis (MS) is a life-long disease that typically affects young adults. The introduction of disease-modifying therapy has changed the clinical and social burden of the disease. Safety, tolerability and efficacy profiles of Interferon beta (IFNbeta) therapy in MS have been widely highlighted both in trial settings and in daily clinical practice. However, there is a relative lack of information on the long-term period: all pivotal trials must be considered short-term in a disease with an average duration of 30-40 years and post-marketing studies suffer from some limitations. Moreover, current available IFNbeta preparations are only partially effective and are difficult to administer, which has led to poor patient compliance. Over the treatment period, a problem could be the development of neutralising antibodies (NAbs) against the drug, which have been related to lessening treatment benefits. Despite these restrictions, IFNbeta still remains the first choice treatment in MS.
多发性硬化症（MS）是一种通常影响年轻成年人的终身疾病。疾病修饰疗法的引入改变了该疾病的临床和社会负担。在试验环境和日常临床实践中，干扰素β（IFNβ）疗法在MS中的安全性、耐受性和疗效已得到广泛强调。然而，关于长期情况的信息相对较少：在一种平均病程为30至40年的疾病中，所有关键试验都必须被视为短期试验，且上市后研究存在一些局限性。此外，目前可用的IFNβ制剂仅部分有效且难以给药，这导致患者依从性较差。在治疗期间，一个问题可能是针对该药物产生中和抗体（NAbs），这与治疗益处的降低有关。尽管有这些限制，IFNβ仍然是MS的首选治疗方法。
